EARLY VEDOLIZUMAB TROUGH LEVELS ARE NOT ASSOCIATED WITH A SHORT-TERM RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

被引：0
|
作者：
Pudilova, Karolina
Duricova, Dana
Kolar, Martin
Malickova, Karin
Hruba, Veronika
Machkova, Nadezda
Vanickova, Radka
Mitrova, Katarina
Lukas, Martin
Vasatko, Martin
Lukas, Milan
Bortlik, Martin
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1894
引用
收藏
页码：S877 / S877
页数：1
相关论文
共 50 条
  • [21] VEDOLIZUMAB TROUGH LEVELS AND ANTIBODIES IN INFLAMMATORY BOWEL DISEASE: UPDATED INITIAL EXPERIENCE
    Al-Bawardy, Badr
    Ramos, Guilherme Piovezani
    Willrich, Maria Alice V.
    Park, Sang
    Raffals, Laura
    Tremaine, William J.
    Loftus, Edward V., Jr.
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S62 - S63
  • [22] VEDOLIZUMAB TROUGH LEVELS AND ANTIBODIES IN INFLAMMATORY BOWEL DISEASE: UPDATED INITIAL EXPERIENCE
    Al-Bawardy, Badr
    Ramos, Guilherme Piovezani
    Willrich, Maria Alice V.
    Park, Sang
    Raffals, Laura
    Tremaine, William J.
    Loftus, Edward V., Jr.
    GASTROENTEROLOGY, 2018, 154 (01) : S89 - S89
  • [23] Role of vedolizumab trough levels in predicting clinical response in Inflammatory Bowel Disease: a multicentre prospective study
    Falzone, M. H.
    Ribaldone, D. G.
    Saracco, G. M.
    Bertani, L.
    Ceccarelli, L.
    Costa, F.
    Bottari, A.
    Fornaroli, G.
    Cusato, J.
    D'Avolio, A.
    Palermiti, A.
    Antonucci, M.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1216 - I1216
  • [24] HIGHER VEDOLIZUMAB TROUGH LEVELS ASSOCIATED WITH REMISSION IN INFLAMMATORY BOWEL DISEASE (IBD) DURING MAINTENANCE THERAPY
    Ungaro, Ryan C.
    Jossen, Jacqueline
    Phan, Becky L.
    Chefitz, Ezra
    Sehgal, Priya
    Jain, Anjali
    Naik, Snehal
    Dubinsky, Marla
    GASTROENTEROLOGY, 2017, 152 (05) : S384 - S385
  • [25] Short-term Response to Adalimumab in Childhood Inflammatory Bowel Disease
    Noe, Joshua D.
    Pfefferkorn, Marian
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : 1683 - 1687
  • [26] Short-term response to Adalimumab in children with inflammatory bowel disease
    Civitelli, F.
    Nuti, F.
    Viola, F.
    Paganelli, M.
    Romeo, E.
    Aloi, M.
    Neaga, M.
    Barbato, M.
    Lucarelli, S.
    Federici, T.
    Cucchiara, S.
    DIGESTIVE AND LIVER DISEASE, 2007, 39 (10) : A51 - A51
  • [27] Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina
    Salkic, Nermin
    Denjagic, Mirela Basic
    Zubcevic, Nada
    Tamburic, Renata
    Husic Selimovic, Azra
    Babic, Emil
    Bevanda, Milenko
    Saray, Aida
    Jovanovic, Predrag
    Tosic, Zoran
    Dobrovoljski, Aleksandar
    Barac, Tatjana
    BIOMOLECULES AND BIOMEDICINE, 2024, 24 (05): : 1400 - 1406
  • [28] Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
    Vaughn, Byron P.
    Yarur, Andres J.
    Graziano, Elliot
    Campbell, James P.
    Bhattacharya, Abhik
    Lee, Jennifer Y.
    Gheysens, Katherine
    Papamichael, Konstantinos
    Osterman, Mark T.
    Cheifetz, Adam S.
    Cross, Raymond K.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 11
  • [29] vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients
    Marino, M.
    Domenis, R.
    Biribin, L.
    Cifu, A.
    Navarria, L.
    Scardino, G.
    Fabris, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S492 - S492
  • [30] Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study
    Yacoub, W.
    Williet, N.
    Pouillon, L.
    Di-Bernado, T.
    Bittencourt, M. De Carvalho
    Nancey, S.
    Lopez, A.
    Paul, S.
    Zallot, C.
    Roblin, X.
    Peyrin-Biroulet, L.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (07) : 906 - 912
12345